<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147560</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCDC20170508</org_study_id>
    <nct_id>NCT03147560</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants</brief_title>
  <official_title>Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Provincial Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of different
      sequential immunization strategies by Sabin IPV and bOPV in Chinese infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Actual">December 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seroconversion rate</measure>
    <time_frame>seroconversion rate was evaluated 4-5 weeks after the third dose of polio vaccine.</time_frame>
    <description>any positive antibody response in infants who were seronegative prior to their first dose, or at least a fourfold increase in type-specific antibody levels for infants who had pre-existing antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety: rate of adverse events</measure>
    <time_frame>At least 2 active surveillance visits (3 days and 30 days) were required after each vaccination to collect adverse reaction data.</time_frame>
    <description>the rate of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutralizing antibody titer</measure>
    <time_frame>Blood samples were obtained prior to the first dose and 4-5 weeks after the third dose of polio vaccine.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">528</enrollment>
  <condition>Polio</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sabin IPV+ bOPV+ bOPV</intervention_name>
    <description>Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sabin IPV + Sabin IPV + bOPV</intervention_name>
    <description>Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sabin IPV + Sabin IPV + Sabin IPV</intervention_name>
    <description>Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent/legal acceptable representative is willing and able to understand the protocol
             requirements and provide informed consent.

          -  Participant is aged ≥ 60 days to ≤ 75 days.

          -  Participant without preventive inoculation of polio vaccine and previous history of
             Polio.

          -  Subject and parent/guardian able to attend all scheduled visits and comply with all
             trial procedures.

          -  Body temperature ≤ 37.5℃.

        Exclusion Criteria:

          -  Known allergy to any constituent of the vaccine.

          -  Known acute illness, severe chronic disease, acute exacerbation of chronic disease and
             fever.

          -  Known or suspected impairment of immunologic function, or receipt of immunosuppressive
             therapy or immunoglobulin since birth.

          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain
             disease and clear serious systemic reaction.

          -  Known bleeding disorder.

          -  Receipt of the whole blood, blood plasma or immunoglobulin before the trial
             vaccination.

          -  Reported the history of acute illness had need systemic antibiotics or antiviral
             treatment of infections in the 7 days preceding the trial vaccination.

          -  An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding
             enrollment in the trial.

          -  Participation in any other intervention clinical trial.

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the subject or interfere with the vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>75 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chunan Center for Disease Control and Prevention</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longyou Center for Disease Control and Prevention</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Sabin IPV</keyword>
  <keyword>bOPV</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

